OTCMKTS:ARYX

ARYx Therapeutics Competitors

$0.01
0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.02
52-Week Range
$0.00
$0.05
Volume5,700 shs
Average Volume120,934 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.53

Competitors

ARYx Therapeutics (OTCMKTS:ARYX) Vs. ACUS, AFFY, AHROQ, CBPI, CDSG, and CHHE

Should you be buying ARYX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ARYx Therapeutics, including Acusphere (ACUS), Affymax (AFFY), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), and China Health Industries (CHHE).

Acusphere (OTCMKTS:ACUS) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Acusphere and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Volatility and Risk

Acusphere has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Acusphere and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
ARYx Therapeutics0000N/A

Valuation and Earnings

This table compares Acusphere and ARYx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Summary

Acusphere beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Affymax and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Volatility and Risk

Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Affymax and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
ARYx Therapeutics0000N/A

Valuation and Earnings

This table compares Affymax and ARYx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Summary

Affymax beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Valuation and Earnings

This table compares ARYx Therapeutics and AtheroNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Volatility & Risk

ARYx Therapeutics has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, meaning that its stock price is 971% less volatile than the S&P 500.

Profitability

This table compares ARYx Therapeutics and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
AtheroNovaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ARYx Therapeutics and AtheroNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
AtheroNova0000N/A

Summary

ARYx Therapeutics beats AtheroNova on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for ARYx Therapeutics and China Botanic Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
China Botanic Pharmaceutical0000N/A

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, meaning that its share price is 1,609% more volatile than the S&P 500.

Valuation & Earnings

This table compares ARYx Therapeutics and China Botanic Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Summary

China Botanic Pharmaceutical beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and ARYx Therapeutics (OTCMKTS:ARYX) are both consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for China Dongsheng International and ARYx Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
ARYx Therapeutics0000N/A

Volatility & Risk

China Dongsheng International has a beta of 13.38, meaning that its share price is 1,238% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500.

Profitability

This table compares China Dongsheng International and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares China Dongsheng International and ARYx Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Summary

China Dongsheng International beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and China Health Industries (OTCMKTS:CHHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares ARYx Therapeutics and China Health Industries' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A

China Health Industries has higher revenue and earnings than ARYx Therapeutics.

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ARYx Therapeutics and China Health Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
China Health Industries0000N/A

Profitability

This table compares ARYx Therapeutics and China Health Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
China Health Industries34.11%8.60%7.05%

Summary

China Health Industries beats ARYx Therapeutics on 5 of the 5 factors compared between the two stocks.


ARYx Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.79flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.06flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.